Elucidating mechanisms of therapy response in BRCA2 mutant prostate cancers
阐明 BRCA2 突变前列腺癌的治疗反应机制
基本信息
- 批准号:10678578
- 负责人:
- 金额:$ 3.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAddressAffectBRCA2 geneBindingBiochemicalBiologicalBiological AssayBiological ModelsBreast Cancer TreatmentCaliforniaCancer PatientCell LineCell SurvivalCessation of lifeChromatinClinicalClinical TrialsCollagenCollagen Type IDNA DamageDataDepositionExtracellular MatrixExtracellular Matrix DegradationFailureFibronectinsFibrosisGene set enrichment analysisGenesGenetic TranscriptionGenomicsGleanGoalsGrantHormonalHourImpairmentIn VitroIncidenceKnowledgeLamininLinkMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMetalloproteasesModelingMolecularMutationPathogenicityPathologicPathway interactionsPatientsPhosphotransferasesPlasminPlasminogen Activator Inhibitor 1Poly(ADP-ribose) Polymerase InhibitorPoly(ADP-ribose) PolymerasesPolymerasePromoter RegionsProstateProteinsRNA analysisRecurrenceResistanceResistance developmentRiskRoleSERPINE1 geneSan FranciscoSignal PathwaySignal TransductionSolid NeoplasmStainsSystemTissuesTranscriptional ActivationTrichrome stainUnited StatesUnited States Food and Drug AdministrationUniversitiesUp-RegulationUrokinaseadvanced breast canceradvanced prostate cancercancer cellcarcinogenesiscastration resistant prostate cancerclinical prognosisclinically relevantin vitro activityin vivoin vivo Modelinhibitorinhibitor therapymenmutantnew therapeutic targetnoveloverexpressionpatient derived xenograft modelpreventprostate cancer modelresponsesmall moleculetherapy resistanttranscription factor USFtranscriptome sequencingtreatment responsetumor
项目摘要
ABSTRACT
Prostate cancer is the most common non-skin malignancy in men and is projected to cause 34,500 deaths in
2022 in the United States alone. Sequencing studies of advanced lethal castrate resistant prostate cancer
(CRPC) have identified a high incidence (~13%) of pathogenic BRCA2 mutations. These findings have enabled
clinical trials and subsequent Food and Drug Administration (FDA) approval of the poly (ADP-ribose) polymerase
(PARP) inhibitors (PARPis) olaparib and rucaparib in advanced CRPC patients harboring a pathogenic BRCA2
mutations. Despite initial responses, therapy resistance to PARPis is common. However, the molecular
adaptations that occur in BRCA2 mutant CRPC in response to PARPi are poorly understood, due to a lack of
biologically and clinically relevant models. Our proposed studies leveraging two new patient-derived model
systems of pathogenic BRCA2 mutant CRPC will elucidate the biological mechanisms implicated in PARPi
therapy response and help address a critical clinical unmet need to prevent or overcome resistance to PARPis.
In this proposal, we will use two new models of pathogenic BRCA2 mutations in CRPC, including the 40511
cell line and matched PARPi-sensitive and resistant LTL-610 PDXs. Gene Set Enrichment Analysis (GSEA) and
Over-Representation Analysis (ORA) of RNA-sequencing data utilizing these novel models point to significant
upregulation in genes involved in Extracellular Matrix (ECM) modulation in response to both short and long term
PARPi therapy. In particular, the ECM associated gene SERPINE1, which encodes for the protein Plasminogen
Activator Inhibitor 1, (PAI-1) is the most significantly implicated gene after 72 hours of olaparib treatment via
GSEA leading edge analysis. Since PAI-1 canonically prevents ECM degradation, we then used Masson’s
Trichrome staining to evaluate the PARPi resistant LTL-610 PDX and found dramatically increased Type I
Collagen deposition compared to its PARPi sensitive parental line. Since stromal alterations are known to affect
cancer cell survival, we hypothesize that the induction of ECM genes like SERPINE1 by PARPis in BRCA2
mutant CRPC results in enhanced tumor stroma, and enables therapy resistance. Two specific aims are
proposed in this grant to study this hypothesis: in Aim 1, we will elucidate the role of SERPINE1 signaling in
ECM deposition in BRCA2 mutant CRPC in vitro, ex vivo, and in vivo. In Aim 2, we will investigate the mechanism
of transcriptional activation of SERPINE1 in BRCA2 mutant CRPC in response to PARPi. The results from these
studies will enable systematic approaches to modulate ECM alterations in response to PARPi in BRCA2 mutant
CRPCs.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mia E Hofstad其他文献
Mia E Hofstad的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 3.84万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 3.84万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 3.84万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 3.84万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 3.84万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 3.84万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 3.84万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 3.84万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 3.84万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 3.84万 - 项目类别:
Research Grant